Cancer and Blood Disorders

Show Only Open Trials
1.

Tocilizumab (an anti-human IL-6 receptor monoclonal antibody) as a first line therapy for patients with glucocorticoid-refractory acute graft vs. host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (HSCT), a Phase II study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Steroid-Refractory Acute Graft-versus-Host Disease (GVHD)
2.

A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft versus Host Disease (cGVHD)

  • Study Status: Open to Enrollment
  • Sponsor: Therakos
  • Disease Status and/or Stage: Moderate to Severe Graft-versus-Host Disease (GVHD)
3.

RDCRN 6503: Targeted Therapy of Bronchiolitis Obliterans Syndrome

  • Study Status: Open to Enrollment
  • Sponsor: NIH, GVHD Consortium
  • Disease Status and/or Stage: Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplant (HCT)
4.

RDCRN 6502: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation

  • Study Status: Open to Enrollment
  • Sponsor: NIH, GVHD Consortium
  • Disease Status and/or Stage: Cutaneous Sclerosis after Hematopoietic Cell Transplant (HCT); blood disorders; rituximab; imatinib; Sebastian Mayer MD; Weill Cornell Bone Marrow Transplant; stem cell transplant; New York Presbyterian Hospital
  • Protocol ID: RDCRN 6502
5.

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

  • Study Status: Open to Enrollment
  • Sponsor: Fresenius Biotech GmbH
  • Disease Status and/or Stage: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
  • Protocol ID: IV-ATG-SCT-01
6.

A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Advanced or Metastatic Kidney Cancer
  • Protocol ID: BMS CA209-025-041
7.

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: OncoMed
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
  • Protocol ID: 52M51-001
8.

An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Janssen
  • Disease Status and/or Stage: Refractory Follicular Lymphoma
  • Protocol ID: PCI-32765FLR2002
9.

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100

  • Study Status: Open to Enrollment
  • Sponsor: Exelixis
  • Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
  • Protocol ID: XL184-307
10.

An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Protocol ID: PCYC 1117-CA
11.

S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplatic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Higher Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
  • Protocol ID: S1117
12.

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: AstraZeneca
  • Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
13.

A phase II study of brentuximab vedotin as salvage therapy for Hodgkin Lymphoma prior to autologous hematopoietic stem cell transplantation

  • Study Status: Open to Enrollment
  • Sponsor: City of Hope
  • Disease Status and/or Stage: Relapsed or Refractory to One Frontline Induction Therapy
14.

Phase III, Multicenter, Randomized, Trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML (protocol CLTR0310-301)

  • Study Status: Open to Enrollment
  • Sponsor: Celator
  • Disease Status and/or Stage: Newly Diagnosed High Risk AML, Age 60 to 75
15.

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Study Status: Open to Enrollment
  • Sponsor: Astellas Pharma
  • Disease Status and/or Stage: Relapsed or Refractory Acute Myeloid Leukemia (AML); AC220; ASP2689; blood cancer treatment; Ellen Ritchie; Gail Roboz; Weill Cornell Leukemia: New York Presbyterian Hospital
16.

Phase II Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a diagnosis of Intermediate-2 or High-Risk PM, Post-PV Myelofibrosis, or Post-ET Myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Sanofi Aventis
17.

Phase 3 randomized study to evaluate the substitution of Marqibo for standard vincristine sulfate injection in combination chemotherapy for subjects ≥ 60 yrs old w/ newly diagnosed ALL

  • Study Status: Open to Enrollment
  • Sponsor: Talon Therapeutics
  • Disease Status and/or Stage: Newly Diagnosed ALL, Age 60 and Older
18.

A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse

  • Study Status: Open to Enrollment
  • Sponsor: CSL Limited
19.

A Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Kinex
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML) in Subjects Age 60 and Older
20.

A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

  • Study Status: Open to Enrollment
  • Sponsor: Ely Lilly
  • Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
21.

Phase II randomized controlled trial of pegylated interferon alpha-2b in early primary myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Low or Intermediate Stage Primary Myelofibrosis (PMF)
22.

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center
  • Disease Status and/or Stage: Newly Diagnosed Acute Promyelocytic Leukemia
23.

A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
24.

An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Pfizer
  • Disease Status and/or Stage: Relapsed/Refractory Acute Lymphoblastic Leukemia
25.

A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

  • Study Status: Open to Enrollment
  • Sponsor: Ariad
  • Disease Status and/or Stage: Newly Diagnosed Chronic Myeloid Leukemia
  • Protocol ID: AP24534-12-301
26.

An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy in Women with Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Synta
  • Disease Status and/or Stage: Previously Untreated Metastatic HER2-Positive or Triple Negative Breast Cancer
27.

A Double-blind, Randomized Phase II Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Optimer Biotechnology
  • Disease Status and/or Stage: Metastatic Breast Cancer
28.

A Phase I/II Trial of Temsirolimus Plus Neratinib for Subjects with Metastatic HER2-Amplified or Triple Negative Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Puma
  • Disease Status and/or Stage: HER2-Positive Metastatic Breast Cancer
29.

Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
  • Disease Status and/or Stage: Metastatic Epithelial Cancer
30.

A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients with CLL

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated CLL
31.

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Study Status: Open to Enrollment
  • Sponsor: Allos Therapeutics
  • Disease Status and/or Stage: Peripheral T-Cell Lymphoma
  • Protocol ID: PDX-017
32.

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Hoffmann-La Roche/Genentech
  • Disease Status and/or Stage: Advanced or Metastatic HER2-Positive Gastric or GEJ Cancer
  • Protocol ID: BO27952
33.

A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mutliple Myeloma
34.

A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's)

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Refractory Lymphoma (non-Hodgkin and Hodgkin) in Need of Stem Cell Transplant
35.

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

  • Study Status: Open to Enrollment
  • Sponsor: Nektar Therapeutics
  • Disease Status and/or Stage: Locally Recurrent or Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
36.

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

  • Study Status: Open to Enrollment
  • Sponsor: National Cord Blood Program
  • Disease Status and/or Stage: Hematologic Malignancies and Other Indications Receiving Allogeneic Hematopoieic Stem Cell Transplant
37.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib( GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Previously Treated, Recurrent CLL
  • Protocol ID: GS1101-0115
38.

A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma or Burkitt Lymphoma
  • Protocol ID: C14011
39.

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
  • Protocol ID: MLN 16010
40.

Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Previously Treated, Metastatic Ovarian, Fallopian Tube or Primary Peritoneal Cancer
41.

Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

  • Study Status: Open to Enrollment
  • Sponsor: NCI
  • Disease Status and/or Stage: Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
42.

A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

  • Study Status: Open to Enrollment
  • Sponsor: Gynecologic Oncology Group; National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced Cervical Cancer
43.

Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Montefiore Medical Center
  • Disease Status and/or Stage: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
44.

A Phase Ib Study of Fractionated 90Y-hPAM4 with or without Gemcitabine in Patients with Metastatic Pancreatic Cancer who Received at Least Two Prior Treatments

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
  • Disease Status and/or Stage: Stage IV Metastatic Pancreatic Cancer
  • Protocol ID: IM-T-hPAM4-03
45.

Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
46.

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Onyx Pharmaceuticals
  • Disease Status and/or Stage: Relapsed Multiple Myeloma
  • Protocol ID: 2011-003
47.

An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal (GEJ) Cancer
48.

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Protocol ID: PCYC-1112-CA
49.

A Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
50.

Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Follicular Lymphoma
51.

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
  • Disease Status and/or Stage: Untreated Mantle Cell Lymphoma, Age 60 & Older
  • Protocol ID: E1411
52.

N093B: Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Cancer Trials Support Unit (CTSU)
  • Disease Status and/or Stage: Triple Negative Metastatic Breast Cancer
  • Protocol ID: N093B
53.

PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxâ„¢ Treatment

  • Study Status: Open to Enrollment
  • Sponsor: Galena Biopharma
  • Disease Status and/or Stage: HER2 1+/2+, Node Positive Breast Cancer
54.

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell Lymphoma
  • Protocol ID: C14012
55.

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Genentech
  • Protocol ID: YO28252
56.

A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma; No Previous Treatment
57.

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Janssen
58.

BMS CA204007: A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Multiple Multiple and Normal Renal Function, Severe Renal Impairment, or on Dialysis
  • Protocol ID: BMS CA204007
59.

An Open-label Phase 2 Study of ACE-041 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Study Status: Open to Enrollment
  • Sponsor: Acceleron
  • Disease Status and/or Stage: Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
60.

A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
61.

A Study of Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Genentech/Roche
  • Disease Status and/or Stage: Metastatic Gastric Cancer
62.

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

  • Study Status: Open to Enrollment
  • Sponsor: Bayer HealthCare
  • Disease Status and/or Stage: Metastatic Colon Cancer
  • Protocol ID: 15967
63.

BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

  • Study Status: Open to Enrollment
  • Sponsor: BMT-CTN
  • Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
  • Protocol ID: BMT CTN 0903
64.

CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Resected Stage III Colon Cancer
  • Protocol ID: CALGB 80702
65.

CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission of Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Bulky, Early Stage Hodgkin Lymphoma
66.

CALGB 50604: Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Hodgkin Lymphoma, Stage IA, IB, IIA or IIB
  • Protocol ID: CALGB 50604
67.

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

  • Study Status: Open to Enrollment
  • Sponsor: GlaxoSmithKline
  • Disease Status and/or Stage: Kidney Cancer, Surgically Removed
68.

CALGB 90802: Randomized phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal cell carcinoma progressing after treatment with tyrosine kinase inhibitors

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Advanced Kidney Cancer
  • Protocol ID: CALGB 90802
69.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Patients with Previously Treated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Gilead Sciences, Inc.
  • Disease Status and/or Stage: Previously Treated Chronic Lymphocytic Leukemia (CLL)
  • Protocol ID: 0116
70.

A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients with Waldenström Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: National Comprehensive Cancer Network (NCCN)
  • Disease Status and/or Stage: Untreated Waldenstrom Macroglobulinemia
71.

A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients with Previously Treated Waldenstrom Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Previously Treated Waldenstrom Macroglobulunemia
72.

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

  • Study Status: Open to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
  • Protocol ID: MPD-RC 111
73.

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

  • Study Status: Open to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Polycythemia Vera (PV)
74.

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
75.

A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Plexxikon
76.

CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50901
77.

CALGB 10801: Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML) with Core Binding Factor Abnormaility
  • Protocol ID: CALGB 10801
78.

CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
79.

S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: SWOG
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
80.

Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
81.

Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

  • Study Status: Open to Enrollment
  • Sponsor: Calistoga
  • Disease Status and/or Stage: Refractory Indolent B-cell non-Hodgkin Lymphoma
82.

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50904
83.

A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
84.

An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma (non-Hodgkin and Hodgkin)
85.

Clinical Database and Tissue Repository Collection Project for the Study of Waldenstrom's Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
86.

BMS CA204004: A Phase 3, Randomized, Open-Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma

  • Study Status: Closed to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
87.

Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress)

  • Study Status: Open to Enrollment
  • Sponsor: Agency for Healthcare Research and Quality; Weill Cornell Medical College
88.

E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)

  • Study Status: Open to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
89.

REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Oncolytics Biotech, Inc.
  • Disease Status and/or Stage: Colon Cancer
90.

CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: FLT3 Mutated Acute Myeloid Leukemia
91.

CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Acute Myeloid Leukemia
92.

REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

  • Study Status: Open to Enrollment
  • Disease Status and/or Stage: Advanced or Metastatic Pancreatic Cancer
93.

A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects with Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

  • Study Status: Closed to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Advanced/Metastatic Renal Cell Carcinoma (RCC)
94.

A Phase II Study of Tetrathiomolybdate (TM) in patients with breast cancer at moderate to high risk of recurrence

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: High-Risk Stage II Breast Cancer; Stage III Breast Cancer; Stage IV Breast Cancer in Remission
95.

Prospective Data Collection Among Women Using Cold Caps During TC Chemotherapy

  • Study Status: Open to Enrollment
  • Disease Status and/or Stage: Early-Stage Breast Cancer
96.

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Lilly
  • Disease Status and/or Stage: Stage IV Non-Small Cell Lung Cancer
97.

A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)

  • Study Status: Open to Enrollment
  • Sponsor: Cougar Biotechnology
  • Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
98.

Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
99.

Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Diffuse Large B-Cell Lymphoma (DLBCL)
100.

Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
101.

A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics, Inc.
102.

A Phase 1/2 Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

  • Study Status: Closed to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Untreated Multiple Myeloma
103.

An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma

  • Study Status: Closed to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
104.

An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

  • Study Status: Closed to Enrollment
  • Sponsor: Genentech
  • Disease Status and/or Stage: Previously Treated t(4;14)-positive Multiple Myeloma
105.

Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
106.

A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

  • Study Status: Open to Enrollment
  • Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
107.

An Open-Label Phase I Study of BB-10901 (IMGN901, huN901-DM1) in Combination with Lenalidomide and Dexamethasone in Patients with CD56- positive Relapsed or Relapsed/Refractory Multiple Myeloma

  • Study Status: Closed to Enrollment
  • Sponsor: ImmunoGen, Inc.
108.

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

  • Study Status: Open to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
109.

Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
110.

Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
111.

Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematological Malignancies
112.

A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

  • Study Status: Open to Enrollment
  • Sponsor: Sunesis Pharmaceuticals
  • Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
113.

Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine

  • Study Status: Open to Enrollment
  • Sponsor: Onconova Therapeutics, Inc
  • Disease Status and/or Stage: Myelodysplastic Syndromes (MDS) Including RAEB and Chronic Myelomonocytic Leukemia (CMML)
114.

CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB; NCI; Eastern Cooperative Oncology Group; Southwest Oncology Group
  • Disease Status and/or Stage: Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
  • Protocol ID: CALGB 10403
115.

A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

  • Study Status: Open to Enrollment
  • Sponsor: SuperGen
  • Disease Status and/or Stage: Intermediate-2 or high-risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
116.

Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated Hodgkin Lymphoma
117.

Phase 1 Study of Radiosensitization using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma receiving Radioimmunotherapy

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed or Refractory Non-Hodgkin's Lymphoma
118.

A Phase II, Single Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel®) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
119.

CALGB 50303: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B; National Cancer Institute
  • Disease Status and/or Stage: Untreated De Novo Diffuse Large B-Cell Lymphoma with Stage II, III or IV Disease
120.

Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) of Any Stage
121.

MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

  • Study Status: Closed to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: Polycythemia Vera (PV)
122.

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS)

  • Study Status: Closed to Enrollment
  • Disease Status and/or Stage: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
123.

Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College; Immunomedics, Inc.
124.

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B, National Cancer Institute
  • Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
125.

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Castration-Resistant Prostate Cancer
126.

Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Prostate Cancer
127.

A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Metastatic Androgen-Independent Prostate Cancer

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic, Hormone-Refractory Prostate Cancer
128.

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed Prostate Cancer
129.

A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Prostate Cancer
130.

A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy

  • Study Status: Open to Enrollment
  • Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
  • Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
131.

A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors

  • Study Status: Closed to Enrollment
  • Sponsor: BiPar Sciences
  • Disease Status and/or Stage: Metastatic Pancreatic Cancer
132.

A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.

  • Study Status: Closed to Enrollment
  • Sponsor: Immunomedics, Inc.
  • Disease Status and/or Stage: Untreated Advanced Pancreatic Cancer
133.

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients

  • Study Status: Open to Enrollment
  • Sponsor: Tragara Pharmaceuticals
  • Disease Status and/or Stage: Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
134.

Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)

  • Study Status: Open to Enrollment
  • Sponsor: Eli Lily & Co.
  • Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
135.

CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B, National Cancer Institute
  • Disease Status and/or Stage: Non-small Cell Lung Cancer
136.

A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College, National Cancer Institute
  • Disease Status and/or Stage: Metastatic or Advanced Kidney Cancer
137.

A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College, National Cancer Institute
  • Disease Status and/or Stage: Advanced, Unresectable and/or Metastatic Kidney Cancer
138.

ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)

  • Study Status: Closed to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
  • Disease Status and/or Stage: Renal Cell Cancer
139.

A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Mayo Clinic, National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
140.

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
  • Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
141.

A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Solid Tumor
142.

A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients with Advanced Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Eisai
  • Disease Status and/or Stage: Advanced Breast Cancer and Neuropathy
143.

Phase II study of ixabepilone in patients with metastatic breast cancer and a prospective evaluation of its effects on the ultrastructure of neurons

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College; Bristol-Myers Squibb
  • Disease Status and/or Stage: Metastatic Breast Cancer
144.

ACOSOG Z1072: A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: American College of Surgeons/National Cancer Institute
  • Disease Status and/or Stage: Invasive Breast Cancer
145.

A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer

  • Study Status: Closed to Enrollment
  • Sponsor: GlaxoSmithKline
  • Disease Status and/or Stage: Metastatic Breast Cancer
146.

A Randomized Placebo-Controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients with a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy

  • Study Status: Open to Enrollment
  • Disease Status and/or Stage: Breast Cancer, any stage
147.

A Phase II Study of Tetrathiomolydate (TM) in patients with breast cancer at moderate to high risk for recurrence

  • Study Status: Open to Enrollment
  • Disease Status and/or Stage: Breast Cancer at moderate to high risk of recurrence (based on the number of lymph nodes); Stage 4 breast cancer without any evidence of disease
Top of page